Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid every 3 months versus every 4 weeks after about 1 year of prior treatment in breast cancer with bone metastases
2005-004942-15Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zoledronic acid in breast cancer and bone metastases (2 arms), sponsored by Novartis. Primary endpoint: Annual overall skeletal morbidity rate. Started Jan 2006; status: completed.
02
Drugs
zoledronic acid
03
Conditions
breast cancerbone metastases
Beyond the preview
Go deeper on 2005-004942-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004942-15.